PHS
PTLA

PFM Health Sciences’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

PFM Health Sciences’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-533,300
Closed -$17.4M – 130
2018
Q1 		$17.4M Buy
+533,300
New +$23.4M 0.35% 75

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PFM Health Sciences's PTLA Position: Q4 2018 in Review

PFM Health Sciences sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 4,600,847 shares — an estimated $123M sold.

PFM Health Sciences first reported a position in PTLA in Q4 2016 and held it in 8 quarters. The position peaked at $289M in Q4 2017. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • PFM Health Sciences reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • PFM Health Sciences sold 4,600,847 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $123M.
  • PFM Health Sciences first reported a position in Portola Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
  • PFM Health Sciences's Portola Pharmaceuticals, Inc. position peaked at $289M in Q4 2017.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on PFM Health Sciences's 13F filing for Q4 2018, filed 14 Feb 2019.